Conclusion of a significant purchase order
The Management Board of Selvita S.A. with its registered office in Krakow (“Selvita” or “Issuer”) hereby announces that its affiliated company – Selvita d.o.o. (“Company”) with its registered offices in Zagreb, Croatia received on the 1st of August 2022 a purchase order (“Order”) under a framework of Research Service Agreement executed on 16th of July 2015, amended as of 18th July 2022 between the Company and one of the largest pharmaceutical company with its registered offices in Europe (“Client”).
In accordance with the Order until July 31st, 2023 the Company shall provide ADME/DMPK services including physicochemical profiling and analytical services to the Client that will support its research programs with a total indicative value of EUR 2,200,000 (PLN 10,360,240 converted at the rate EUR 1 = PLN 4.7092). The exact value of the Order will be based on a number of performed assays.
The total value of the collaboration between Selvita together with its affiliates and the Client in the first six months of 2022 amounts to EUR 1,705,115 (PLN 8,029,728 converted at the above rate).
Taking into account the value of the Order, as well as the fact that the Client has extended cooperation with the Company, Issuer’s Management Board considers the Order to be significant for the implementation of Selvita Group’s long-term plans aiming at building a strong position on the international preclinical CRO market.
Legal basis: Art. 17.1 MAR
Representatives of the Company:
- Miłosz Gruca – Vicepresident of the Management Board
- Dawid Radziszewski – Member of the Management Board